[Preprint] Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial, 2023, Bramante et al.

Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial
Carolyn T Bramante; Kenneth B Beckman; Tanvi Mehta; Amy B Krager; David J Odde; Christopher J Tignanelli; John B Buse; Darnell M Johnson; Ray H B Watson; Jerry J Daniel; David M Liebovitz; Jacinda M Nicklas; Kenneth Cohen; Michael A Puskarich; Hrishikesh K Belani; Lianne K Siegel; Nichole R Klatt; Blake Anderson; Katrina M Hartman; Via Rao; Aubrey A Hagan; Barkha Patel; Sarah L Fenno; Nandini Avula; Neha V Reddy; Spencer M Erickson; Regina D Fricton; Samuel Lee; Gwendolyn Griffiths; Matthew F Pullen; Jennifer L Thompson; Nancy Sherwood; Thomas A Murray; Michael R Rose; David R Boulware; Jared D Huling

Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot be used with many medications, and are limited to virus-specific targets. Biophysical modeling of SARS-CoV-2 replication predicted that protein translation is an especially attractive target for antiviral therapy. Literature review identified metformin, widely known as a treatment for diabetes, as a potential suppressor of protein translation via targeting of the host mTor pathway. In vitro, metformin has antiviral activity against RNA viruses including SARS-CoV-2.

In the COVID-OUT phase 3, randomized, placebo-controlled trial of outpatient treatment of COVID-19, metformin had a 42% reduction in ER visits/hospitalizations/death through 14 days; a 58% reduction in hospitalizations/death through 28 days, and a 42% reduction in Long COVID through 10 months. Here we show viral load analysis of specimens collected in the COVID-OUT trial that the mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (-0.56 log10 copies/mL; 95%CI, -1.05 to -0.06, p=0.027) while there was no virologic effect for ivermectin or fluvoxamine vs placebo. The metformin effect was consistent across subgroups and with emerging data.

Our results demonstrate, consistent with model predictions, that a safe, widely available, well-tolerated, and inexpensive oral medication, metformin, can be repurposed to significantly reduce SARS-CoV-2 viral load.

Link | PDF (Preprint: MedRxiv)

 

Does it also work for people who are not overweight or obese?

 

Now published as —

Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019
Bramante, Carolyn T et al.

BACKGROUND
Metformin has antiviral activity against RNA viruses including severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). The mechanism appears to be suppression of protein translation via targeting the host mechanistic target of rapamycin pathway. In the COVID-OUT randomized trial for outpatient coronavirus disease 2019 (COVID-19), metformin reduced the odds of hospitalizations/death through 28 days by 58%, of emergency department visits/hospitalizations/death through 14 days by 42%, and of long COVID through 10 months by 42%.

METHODS
COVID-OUT was a 2 × 3 randomized, placebo-controlled, double-blind trial that assessed metformin, fluvoxamine, and ivermectin; 999 participants self-collected anterior nasal swabs on day 1 (n = 945), day 5 (n = 871), and day 10 (n = 775). Viral load was quantified using reverse-transcription quantitative polymerase chain reaction.

RESULTS
The mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (−0.56 log10 copies/mL; 95% confidence interval [CI], −1.05 to −.06; P = .027). Those who received metformin were less likely to have a detectable viral load than
placebo at day 5 or day 10 (odds ratio [OR], 0.72; 95% CI, .55 to .94). Viral rebound, defined as a higher viral load at day 10 than day 5, was less frequent with metformin (3.28%) than placebo (5.95%; OR, 0.68; 95% CI, .36 to 1.29). The metformin effect was consistent across subgroups and increased over time. Neither ivermectin nor fluvoxamine showed effect over placebo.

CONCLUSIONS
In this randomized, placebo-controlled trial of outpatient treatment of SARS-CoV-2, metformin significantly reduced SARS-CoV-2 viral load, which may explain the clinical benefits in this trial. Metformin is pleiotropic with other actions that are relevant to COVID-19 pathophysiology.

Clinical Trials Registration. NCT04510194.

Link | PDF (Clinical Infectious Diseases)